Search
Highlights from the SWG
Impactful activitiesSymposium at EHA2023The SWG held a symposium on ‘2. 0 diagnostics in hematology: the role of AI’ at the EHA2023 Congress. EHA2023 took place from June 8–11, 2023, in Frankfurt, Germany.
Read moreNovel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read more1st EHA-Balkan Hematology Day
EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 1st edition of the EHA-Balkan Hematology Day.
Read morePatient organizations
EHA greatly values the collaboration with patient organizations in a growing number of areas, from joint advocacy and a strong presence at the EHA Annual Congress – with a prominent place for the EHA-Patient Joint Symposium on policy and regulatory…
Read moreEHA-ISHBT Hematology Tutorial 2020
The 4th EHA-ISHBT Hematology Tutorial on Hematological Disorders was held on February 28 and 29 in Chandigarh, India, and chaired by Prof John Gribben, Prof Neelam Varma and Prof Pankaj Malhotra.
Read moreCOST Action ‘EuNet-INNOCHRON’
The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.
Read morePublications
The publications of the ESLHO networks can be found on the following pages:
EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.
Chronic Myeloid Leukemia
The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.
Read moreBreakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?
APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »